MP
RYTM icon

Mangrove Partners’s Rhythm Pharmaceuticals RYTM Stock Holding History

Mangrove Partners’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-57,138
Closed -$1.27M – 57
2020
Q2 		$1.27M Buy
+57,138
New +$1.11M 0.31% 43

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Mangrove Partners's RYTM Position: Q3 2020 in Review

Mangrove Partners sold out of Rhythm Pharmaceuticals (RYTM) in Q3 2020, closing a stake of 57,138 shares — an estimated $1.27M sold.

Mangrove Partners first reported a position in RYTM in Q2 2020 and held it in 1 quarter. The position peaked at $1.27M in Q2 2020. 115 funds tracked by Wall St. Rank hold RYTM as of Q3 2020.

  • Mangrove Partners reported no remaining Rhythm Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Mangrove Partners sold 57,138 Rhythm Pharmaceuticals shares in Q3 2020, an estimated $1.27M.
  • Mangrove Partners first reported a position in Rhythm Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Mangrove Partners's Rhythm Pharmaceuticals position peaked at $1.27M in Q2 2020.
  • 115 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2020.

Based on Mangrove Partners's 13F filing for Q3 2020, filed 16 Nov 2020.